drugset / Trial / NCT00861497

Bifeprunox Extension to Extension Study in Patients With Schizophrenia

NCT00861497

Phase 3 Terminated 11 enrolled H. Lundbeck A/S Solvay Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to provide access to bifeprunox for patients, who have completed previous studies with bifeprunox, and require continued treatment with bifeprunox, other treatment not being adequate. A further purpose is to investigate the safety and side-effects of bifeprunox during long-term treatment.

Timeline

Start
2006-01
Primary completion
2008-01
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bifeprunox Small molecule 20 mg
Subject Bifeprunox Small molecule 30 mg
Subject Bifeprunox Small molecule 40 mg

Indications